EGFR and non-small cell lung carcinoma: ICI-based combination therapy, especially immunotherapy combination chemotherapy and anti-angiogenesis might be the preferred treatment regimen for advanced NSCLC patients with EGFR mutations after EGFR- TKIs failure.